M. Späth

发表

EULAR evidence-based recommendations for the management of fibromyalgia syndrome

K Longley, C Henriksson, A. Silman, 2007, Annals of the rheumatic diseases.

Morphologic aspects of fibromyalgia

D. Pongratz, M. Späth, 1998, Zeitschrift für Rheumatologie.

Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia

D. Pongratz, L. Färber, U. Haus, 2004, Scandinavian journal of rheumatology.

[Color duplex ultrasound imaging of renal arteries and detection of hemodynamically relevant renal artery stenoses].

H. Roskamm, T. Zeller, M. Späth, 2001, Ultraschall in der Medizin.

Treatment of fibromyalgia with tropisetron – dose and efficacy correlations

D. Pongratz, L. Färber, U. Haus, 2004, Scandinavian journal of rheumatology. Supplement.

The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience

R. Kohnen, L. Färber, M. Späth, 2004, Scandinavian journal of rheumatology. Supplement.

Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain.

U. Haus, M. Späth, W. Müller, 2000, Scandinavian journal of rheumatology. Supplement.

Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients

B. Bondy, M. Ackenheil, D. Pongratz, 1999, Neuroscience Letters.

Detection of elevated Nε‐carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia

D. Pongratz, M. Späth, S. Franke, 2005 .

Hypermagnesemia following exposure to acute stress.

M. Späth, H. Classen, P. Marquardt, 1971, Pharmacology.

The long-term outcome of anti-Jo-1-positive inflammatory myopathies

B. Schlotter-Weigel, H. Hautmann, G. Leinsinger, 2004, Journal of Neurology.

Platelet Aggregation Evoked In Vitro and In Vivo by Phosphatidic Acids and Lysoderivatives: Identity with Substances in Aged Serum (DAS)

K. Schumacher, M. Späth, H. Classen, 1979, Thrombosis and Haemostasis.

[Epstein-Barr virus].

M. Späth, H. Feucht, W. Becker, 2010 .

Physiology and pathophysiology of the 5‐HT3 receptor

S. Drechsler, L. Färber, U. Haus, 2004, Scandinavian journal of rheumatology. Supplement.

Magnetic resonance imaging of the parotid gland in patients with Sjögren's syndrome.

T. Vogl, G. Grevers, S. Dresel, 1991, The Journal of rheumatology.

Sjoegren's syndrome: MR imaging of the parotid gland

T. Vogl, J. Lissner, G. Grevers, 2004, European Radiology.

Spectrum of use and tolerability of 5‐HT3 receptor antagonists

L. Färber, U. Haus, M. Späth, 2004, Scandinavian journal of rheumatology. Supplement.

Parotid gland: plain and gadolinium-enhanced MR imaging.

T. Vogl, J. Lissner, G. Grevers, 1990, Radiology.

[Immuno-diagnostic findings in "secondary" Sjögren syndrome in chronic polyarthritis].

G. Grevers, M. Schattenkirchner, M. Späth, 1990, Laryngo-Rhino-Otologie.

Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients

B. Bondy, M. Ackenheil, C. Fischer, 2004, Clinical Rheumatology.

Experimental studies on the intestinal uptake of organic and inorganic magnesium and potassium compounds given alone or simultaneously.

M. Späth, H. Classen, P. Marquardt, 1978, Arzneimittel-Forschung.

Improvement by chlorine of the intestinal absorption of inorganic and organic Mg compounds and of their protective effect against adrenergic cardiopathy.

M. Späth, H. Ebel, H. Classen, 1975, Recent advances in studies on cardiac structure and metabolism.

[Pharmacology and toxicology of directly and indirectly active sympathomimetics].

M. Späth, H. Classen, P. Marquardt, 1972, Die Medizinische Welt.

Influence of symptom-limited stress on blood lactate behaviour in coronary heart disease (CHD) patients.

J. Keul, A. Berg, M. Späth, 1987, European heart journal.

Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?

G. Cruccu, D. Bouhassira, E. Kosek, 2016, European journal of pain.

[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].

K. Bär, C. Sommer, T. Tölle, 2012, Schmerz.

[What helps in back pain? Guideline for symptomatic therapy].

D. Pongratz, M. Späth, 2001, MMW Fortschritte der Medizin.

Current experience with 5-HT3 receptor antagonists in fibromyalgia.

M. Späth, 2002, Rheumatic diseases clinics of North America.

Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.

D. Pongratz, L. Färber, H. Peter, 2000, Scandinavian journal of rheumatology. Supplement.

Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.

L. Färber, M. Späth, D. Welzel, 2000, Scandinavian Journal of Rheumatology. Supplement.

Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.

D. Pongratz, L. Färber, H. Peter, 2001, International journal of clinical pharmacology research.